MAZE - CIK 0001842295
The table below shows Maze Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $20.00M | - | $0.00 | - | $2.50M | $165.00M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $34.15M | $25.19M | $28.11M | $27.58M | $19.86M | $19.55M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $12.40M |
| $7.78M |
| $8.37M |
| $7.82M |
| $6.87M |
| $5.90M |
| Operating income | -$26.55M | -$32.97M | -$36.47M | -$35.40M | -$24.23M | $139.56M |
| Income tax | - | $0.00 | $0.00 | - | -$279.00K | $1.73M |
| Net income | -$24.21M | -$30.09M | -$33.68M | -$32.79M | -$24.75M | $139.06M |
| EPS (diluted) | -$0.45 | -$0.66 | -$0.77 | -$1.15 | -$10.25 | $3.22 |